Free tool
Cell therapy stocks
We cover 6 companies grouped under the Cell therapy theme. The median market value in the group is $37.19M. Across the group, the median move over the past trading day is −0.96%. Price change over the past year runs from −65.8% to −16.2% across the middle 80 percent of the group, with a median of −30.4%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
6 of 86 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| ATRA | Atara Biotherapeutics, Inc. | $9.84 | +27.63% | −44.63% | −19.61% | Nov 12, 2026 |
| INKT | MiNK Therapeutics, Inc. | $11.38 | +7.46% | +2.34% | −21.89% | Nov 12, 2026 |
| TVGN | Tevogen Inc. | $6.97 | +25.13% | −61.70% | −84.85% | Nov 13, 2026 |
| SVA.TO | Sernova Biotherapeutics Inc | 0.11 CAD | −8.33% | −15.38% | −38.89% | Sep 10, 2026 |
| PSH0.DE | Sernova Biotherapeutics Inc | 0.06 EUR | −9.73% | −26.71% | −46.78% | Sep 10, 2026 |
| LGVN | Longeveron Inc. | $0.68 | +11.29% | +14.67% | −12.71% | Nov 4, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.